Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-03-22, Stock:ABBV, The news for the past five days is as follows:
2018-03-15: NEWS1: Pfizer’s Segment-by-Segment Performance in 4Q17.NEWS2: Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie.NEWS3: Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie.NEWS4: 7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock.NEWS5: 7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock.NEWS6: What Analysts Recommend for Novartis in March 2018.NEWS7: 7 Things Vertex Pharmaceuticals&apos; CEO Just Said That Will Probably Make You Want to Buy the Stock.NEWS8: Zacks Market Edge Highlights: Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties and AbbVie.NEWS9: Understanding Merck’s Immunology Segment Performance in 4Q17 and 2017.NEWS10: What These 3 Stocks Near Buys Teach Us About The Market; S&P 500, Dow Jones Futures.
2018-03-16: NEWS1: Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus.NEWS2: Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus.NEWS3: Why Multiple Sclerosis is a Promising but Risky Space?.NEWS4: Why Multiple Sclerosis is a Promising but Risky Space?.NEWS5: Why A Biopharma Buying Spree May Target AstraZeneca, Bristol.NEWS6: Why Multiple Sclerosis is a Promising but Risky Space?.NEWS7: Pharma Stock Roundup: ABBV&apos;s Elagolix Meets Study Goal, MRK&apos;s Keytruda in Focus.NEWS8: 5 Must-See Quotes From AbbVie's Management.NEWS9: 5 Must-See Quotes From AbbVie's Management.NEWS10: 5 Must-See Quotes From AbbVie&apos;s Management.
2018-03-19: NEWS1: J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit.NEWS2: J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit.NEWS3: J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit.NEWS4: The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene.NEWS5: The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene.NEWS6: The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene.NEWS7: See what the IHS Markit Score report has to say about AbbVie Inc..
2018-03-20: NEWS1: 3 Healthcare Stocks Hedge Funds Like the Most.NEWS2: 3 Healthcare Stocks Hedge Funds Like the Most.NEWS3: 3 Healthcare Stocks Hedge Funds Like the Most.
2018-03-21: NEWS1: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS2: iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow.NEWS3: Drug prices continue to climb despite barrage of criticism.NEWS4: AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma.

Answer: Decrease